A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

计划入组 1,343 人 · 首次发布于 2019 年 12 月 13 日

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

计划入组 810 人 · 首次发布于 2021 年 7 月 6 日

Topcon 3D OCT-1 Maestro Reference Database Study II

计划入组 504 人 · 首次发布于 2015 年 5 月 18 日

NAFLD (Stemirna Therapeutics)

1-naphthaleneacetic acid

C₁₂H₁₀O₂

GalNAc-conjugated siRNA therapeutic (liver injury/NAFLD)

NHI-1

United States

Xi'an No.1 Hospital

China

ALPHA-1 FOUNDATION, INC.

United States

Madrigal's Rezdiffra Shows Promise in MASH Cirrhosis with Two-Year Data

Madrigal's Resmetirom Nears Full Approval for NASH Cirrhosis Treatment Following Phase 3 Enrollment Completion

Resmetirom Shows Promise in Treating MASLD/MASH: A Comprehensive Review of Clinical Trials